CHF 978.56
(0.57%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 1.86 Billion CHF | 3.81% |
2022 | 1.79 Billion CHF | 7.43% |
2021 | 1.66 Billion CHF | 34.36% |
2020 | 1.24 Billion CHF | 6.29% |
2019 | 1.16 Billion CHF | 5.95% |
2018 | 1.1 Billion CHF | 3.0% |
2017 | 1.07 Billion CHF | 4.86% |
2016 | 1.02 Billion CHF | 1.74% |
2015 | 1 Billion CHF | 59.46% |
2014 | 629.57 Million CHF | 17.07% |
2013 | 537.77 Million CHF | 12.66% |
2012 | 477.35 Million CHF | 6.55% |
2011 | 447.99 Million CHF | -3.46% |
2010 | 464.05 Million CHF | -2.73% |
2009 | 477.06 Million CHF | -10.8% |
2008 | 534.81 Million CHF | -18.81% |
2007 | 658.73 Million CHF | -4.97% |
2006 | 693.2 Million CHF | 2.31% |
2005 | 677.52 Million CHF | 15.65% |
2004 | 585.82 Million CHF | -9.16% |
2003 | 644.87 Million CHF | 9.18% |
2002 | 590.67 Million CHF | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 1.87 Billion CHF | 0.0% |
2023 Q2 | 1.76 Billion CHF | 0.0% |
2023 Q4 | 1.86 Billion CHF | 0.0% |
2023 FY | 1.86 Billion CHF | 3.81% |
2022 Q4 | 1.79 Billion CHF | 0.0% |
2022 FY | 1.79 Billion CHF | 7.43% |
2022 Q2 | 1.72 Billion CHF | 0.0% |
2021 Q2 | 1.58 Billion CHF | 0.0% |
2021 Q4 | 1.66 Billion CHF | 0.0% |
2021 FY | 1.66 Billion CHF | 34.36% |
2020 Q4 | 1.24 Billion CHF | 0.0% |
2020 FY | 1.24 Billion CHF | 6.29% |
2020 Q2 | 1.17 Billion CHF | 0.0% |
2019 Q4 | 1.16 Billion CHF | 0.0% |
2019 FY | 1.16 Billion CHF | 5.95% |
2019 Q2 | 1.1 Billion CHF | 0.0% |
2018 Q4 | 1.1 Billion CHF | 0.0% |
2018 FY | 1.1 Billion CHF | 3.0% |
2018 Q2 | 1.09 Billion CHF | 0.0% |
2017 Q2 | 1.02 Billion CHF | 0.0% |
2017 Q4 | 1.07 Billion CHF | 0.0% |
2017 FY | 1.07 Billion CHF | 4.86% |
2016 Q2 | 1.02 Billion CHF | 0.0% |
2016 Q4 | 1.02 Billion CHF | 0.0% |
2016 FY | 1.02 Billion CHF | 1.74% |
2015 Q2 | 667.74 Million CHF | 0.0% |
2015 Q4 | 1 Billion CHF | 0.0% |
2015 FY | 1 Billion CHF | 59.46% |
2014 Q4 | 629.57 Million CHF | 0.0% |
2014 FY | 629.57 Million CHF | 17.07% |
2014 Q2 | 549.46 Million CHF | 0.0% |
2013 Q2 | 493.54 Million CHF | 0.0% |
2013 Q4 | 537.77 Million CHF | 0.0% |
2013 FY | 537.77 Million CHF | 12.66% |
2012 Q2 | 453.99 Million CHF | 0.0% |
2012 FY | 477.35 Million CHF | 6.55% |
2012 Q4 | 477.35 Million CHF | 0.0% |
2011 Q2 | 434.23 Million CHF | 0.0% |
2011 Q4 | 447.99 Million CHF | 0.0% |
2011 FY | 447.99 Million CHF | -3.46% |
2010 Q2 | 487.34 Million CHF | 0.0% |
2010 Q4 | 464.05 Million CHF | 0.0% |
2010 FY | 464.05 Million CHF | -2.73% |
2009 Q4 | 477.06 Million CHF | 0.0% |
2009 FY | 477.06 Million CHF | -10.8% |
2008 FY | 534.81 Million CHF | -18.81% |
2007 FY | 658.73 Million CHF | -4.97% |
2006 FY | 693.2 Million CHF | 2.31% |
2005 FY | 677.52 Million CHF | 15.65% |
2004 FY | 585.82 Million CHF | -9.16% |
2003 FY | 644.87 Million CHF | 9.18% |
2002 FY | 590.67 Million CHF | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Relief Therapeutics Holding AG | 76.39 Million CHF | -2336.844% |
Tecan Group AG | 2.07 Billion CHF | 10.244% |
Santhera Pharmaceuticals Holding AG | 109.62 Million CHF | -1598.004% |
Basilea Pharmaceutica AG | 173.28 Million CHF | -974.22% |
Bachem Holding AG | 1.68 Billion CHF | -10.614% |
Molecular Partners AG | 198.35 Million CHF | -838.486% |